Postmarketing safety analysis of remimazolam: Identifying unlabelled serious events

医学 上市后监督 药理学 不利影响
作者
Weiying Ma,Rong Zhang,Fan Liu,Minghui Cao,Haoquan Huang
出处
期刊:European Journal of Anaesthesiology [Lippincott Williams & Wilkins]
卷期号:42 (10): 934-944 被引量:4
标识
DOI:10.1097/eja.0000000000002217
摘要

BACKGROUND: Remimazolam is a new ultra-short-acting benzodiazepine used in anaesthesia, valued for its rapid metabolism and reversibility. Despite its growing clinical use, a comprehensive assessment of its real-world safety profile remains essential. OBJECTIVE: To evaluate the postmarketing safety of remimazolam using adverse event (AE) data from the US and Japanese pharmacovigilance databases. DESIGN: Retrospective analysis of AEs associated with remimazolam using disproportionality analysis techniques. SETTING: FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report database (JADER) from January 2020 to December 2023. PARTICIPANTS: Patients who experienced remimazolam-related AEs reported in the FAERS and JADER databases. MAIN OUTCOME MEASURES: Identification of significant AEs using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network and multiitem gamma Poisson shrinker. Categorisation of AEs using the 'Important Medical Event Terms List' (IME) list (version 26.1). RESULTS: We identified 199 remimazolam-related reports (69 from FAERS, 130 from JADER) revealing 20 significant AEs. Key findings include previously unlabelled serious AEs such as cardiac, cardio-respiratory, and respiratory arrests; nine events classified as Important Medical Events, including hypotension and anaphylaxis; four AEs not included in current Food and Drug Administration (FDA) labelling; and low-frequency but clinically significant off-label events including arrhythmias and postoperative delirium. CONCLUSIONS: While remimazolam shows a generally acceptable safety profile, our pharmacovigilance analysis identified serious unlabelled reactions requiring clinical vigilance. Practice recommendations include judicious administration with balanced crystalloids and comprehensive cardiorespiratory monitoring. Future research should address prospective surveillance of rare serious events, optimal administration protocols to prevent vascular occlusions and investigation of anaphylactic reactions. TRIAL REGISTRATION: Not applicable.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
皮卡丘发布了新的文献求助30
刚刚
1秒前
英姑的应助被漫山采纳,获得10
1秒前
cc完成签到,获得积分10
1秒前
1秒前
星野发布了新的文献求助10
2秒前
qb发布了新的文献求助10
2秒前
2秒前
丘比特的应助被楠楠采纳,获得10
2秒前
YC完成签到,获得积分10
2秒前
在水一方的应助被科研通管家采纳,获得10
3秒前
ding的应助被科研通管家采纳,获得10
3秒前
天天向上的应助被科研通管家采纳,获得30
3秒前
3秒前
wang完成签到,获得积分10
3秒前
yinyinyin发布了新的文献求助10
3秒前
3秒前
Hello的应助被科研通管家采纳,获得10
3秒前
秋风的应助被科研通管家采纳,获得10
3秒前
4秒前
隐形曼青的应助被王亚奇采纳,获得10
4秒前
赘婿的应助被科研通管家采纳,获得10
4秒前
今后的应助被科研通管家采纳,获得10
4秒前
李健的应助被lkh采纳,获得10
4秒前
秋风的应助被科研通管家采纳,获得10
4秒前
睡醒再学完成签到,获得积分10
4秒前
JamesPei的应助被科研通管家采纳,获得10
4秒前
桐桐的应助被科研通管家采纳,获得10
4秒前
秋风的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
5秒前
酷波er的应助被科研通管家采纳,获得10
5秒前
小蘑菇的应助被Wey采纳,获得10
5秒前
SciGPT的应助被科研通管家采纳,获得10
5秒前
NexusExplorer的应助被科研通管家采纳,获得10
5秒前
orixero的应助被科研通管家采纳,获得10
5秒前
5秒前
7ohnny发布了新的文献求助10
5秒前
小蘑菇的应助被科研通管家采纳,获得10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188118
求助须知:如何正确求助?哪些是违规求助? 9575977
关于积分的说明 21844428
捐赠科研通 7785918
什么是DOI,文献DOI怎么找? 3435205
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482065